显影剂市场规模、份额和成长分析（按类型、影像方式、给药途径、应用、最终用户和地区）- 2025-2032 年产业预测

2023 年显影剂造影剂市场规模价值为 54 亿美元，预计将从 2024 年的 55.6 亿美元成长到 2032 年的 70.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 3.0%。

复杂合併症和慢性病的增加导致超音波、X光、核磁共振和电脑断层扫描等诊断影像程序的显着增加。 2022年9月，美国FDA核准了具有高相对率、减少钆剂量特征的新型MRI显影剂钆皮醇，这是一个重要的里程碑。这项进步不仅能提高成像精度，还能增强成人和 2 岁及以上儿童的病患安全性。 Gadopiclenol 的配方满足了日益增长的减轻传统显影剂相关风险的需求，代表了诊断成像技术发展的重要一步，并满足了广泛的医疗保健需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

显影剂市场规模（按类型）

• 市场概况
• 碘显影剂
• 钆基显影剂
• 钡基显影剂
• 微气泡显影剂
• 其他的

显影剂市场规模（依影像诊断方法划分）

• 市场概况
• X射线/CT
• MRI
• 超音波
• 其他的

显影剂市场规模（依给药途径划分）

• 市场概况
• 血管内
• 口腔/直肠
• 其他的

显影剂市场规模（依应用划分）

• 市场概况
• 心血管
• 神经系统疾病
• 癌症
• 胃肠道疾病
• 肌肉骨骼疾病
• 其他的

显影剂市场规模（依最终用户划分）

• 市场概况
• 医院
• 诊断影像中心
• 门诊手术中心
• 其他的

显影剂市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Bayer AG（Germany）
• Bracco Imaging SpA（Italy）
• GE Healthcare（US）
• Guerbet（France）
• Lantheus Medical Imaging, Inc.（US）
• NanoPET Pharma GmbH（Germany）
• Fujifilm Corporation（Japan）
• Beijing Beilu Pharmaceutical Co. Ltd.（China）
• Taejoon Pharm Co. Ltd.（South Korea）
• Jubilant Life Sciences Ltd.（India）
• Siemens Healthineers（Germany）
• Philips Healthcare（Netherlands）
• Cardinal Health（US）
• McDermott International（US）
• Medtronic（Ireland）
• Terumo Corporation（Japan）
• Abbott Laboratories（US）
• Baxter International（US）
• Fresenius Medical Care AG & Co. KGaA（Germany）
• Novartis AG（Switzerland）

结论和建议

Contrast Agents Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 7.05 billion by 2032, growing at a CAGR of 3.0% during the forecast period (2025-2032).

The increasing prevalence of complex comorbidities and chronic conditions is driving a notable rise in diagnostic imaging procedures, including ultrasounds, X-rays, MRIs, and CT scans. A key milestone was achieved in September 2022 when the U.S. FDA approved Gadopiclenol, a novel MRI contrast agent characterized by high relativity and a reduced gadolinium dosage. This advancement enhances imaging precision while ensuring heightened patient safety for both adults and children aged two years and above. Gadopiclenol's formulation addresses the growing need to mitigate risks linked to traditional contrast agents, indicating a significant step forward in the evolution of diagnostic imaging technology and catering to a wide array of healthcare requirements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Contrast Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Contrast Agents Market Segments Analysis

Global Contrast Agents Market is segmented by Type, Imaging Modality, Route of Administration, Application, End User and region. Based on Type, the market is segmented into Iodinated Contrast Agents, Gadolinium-Based Contrast Agents, Barium-Based Contrast Agents, Microbubble Contrast Agents and Others. Based on Imaging Modality, the market is segmented into X-Ray/CT, MRI, Ultrasound and Others. Based on Route of Administration, the market is segmented into Intravascular, Oral/Rectal and Others. Based on Application, the market is segmented into Cardiovascular, Neurological Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders and Others. Based on End User, the market is segmented into Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Contrast Agents Market

The growing acceptance of image-guided surgeries (IGS) represents a pivotal trend within the medical field. As these procedures gain popularity, they play a crucial role in both diagnosing and treating a wide range of medical conditions. This rising demand for accurate, real-time imaging improvements during surgical procedures highlights the need for innovative techniques in data acquisition, processing, and display. Additionally, there is an increasing emphasis on understanding imaging processes and their clinical applications. This landscape creates a significant opportunity for advancements in contrast agents that enhance visualization and precision in image-guided surgical practices.

Restraints in the Contrast Agents Market

The Contrast Agents market faces certain impediments, despite advancements in medical technology and the development of improved contrast agent formulations. A portion of patients still experiences side effects or allergic reactions related to these agents. Although these adverse reactions are relatively infrequent, they can vary in severity, from mild discomfort to critical conditions that require urgent medical intervention. Common symptoms include skin reactions, nausea, and shortness of breath; in rare instances, they can escalate to more serious concerns, such as anaphylaxis. These potential health risks place constraints on the widespread adoption of contrast agents in medical procedures.

Market Trends of the Contrast Agents Market

The Contrast Agents market is poised for significant growth, driven by the increasing prevalence of multiple chronic conditions among the aging population. As nearly 80% of individuals aged 65 and older suffer from at least one chronic ailment, the demand for advanced imaging techniques, facilitated by contrast agents, is surging. This demographic shift, projected to see 77 million seniors in the U.S. by 2034, highlights the urgent need for enhanced diagnostics to address the complexities of managing multiple comorbidities. Consequently, the demand for innovative contrast agents is expected to rise sharply, creating lucrative opportunities for key players in the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Contrast Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Iodinated Contrast Agents
• Gadolinium-Based Contrast Agents
• Barium-Based Contrast Agents
• Microbubble Contrast Agents
• Others

Global Contrast Agents Market Size by Imaging Modality & CAGR (2025-2032)

• Market Overview
• X-Ray/CT
• MRI
• Ultrasound
• Others

Global Contrast Agents Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravascular
• Oral/Rectal
• Others

Global Contrast Agents Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cardiovascular
• Neurological Disorders
• Cancer
• Gastrointestinal Disorders
• Musculoskeletal Disorders
• Others

Global Contrast Agents Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers
• Others

Global Contrast Agents Market Size & CAGR (2025-2032)

• North America (Type, Imaging Modality, Route of Administration, Application, End User)
  • US
  • Canada
• Europe (Type, Imaging Modality, Route of Administration, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Imaging Modality, Route of Administration, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Imaging Modality, Route of Administration, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Imaging Modality, Route of Administration, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging SpA (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoPET Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Beilu Pharmaceutical Co. Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taejoon Pharm Co. Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Life Sciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McDermott International (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations